A Phase 2, Multicenter, Double-blind, Randomized, Placebo-controlled Trial to Assess the Efficacy, Safety, and Tolerability of Repeated Doses of VLS-01 Buccal Film in Participants With Treatment Resistant Depression
Latest Information Update: 01 Jul 2025
At a glance
- Drugs N-N-dimethyltryptamine (Primary)
- Indications Depression
- Focus Proof of concept; Therapeutic Use
- Acronyms Elumina
- Sponsors ATAI Life Sciences
Most Recent Events
- 11 Mar 2025 According to a atai Life Sciences media release, company Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression
- 10 Jan 2025 event According to a atai Life Sciences media release, Topline data from the Phase 2 study is anticipated in the first quarter of 2026.
- 03 Jan 2025 Status changed from not yet recruiting to recruiting.